Tactic: tuberculosis active case tracking via interpersonal connections

Active Grant Awarded Last action

Award ID
R01AI191221
Recipient
Awarding agency
Obligated
$783,774

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 9% complete
Place of performance
Roxbury, MA 02118, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation (doing business as BMC) $783,774 under Allergy and Infectious Diseases Research (CFDA 93.855) on June 19, 2026, through grant R01AI191221.

The award funds the TACTIC study (Tuberculosis Active Case Tracking via Interpersonal Connections), which evaluates respondent-driven sampling, a peer-based community recruitment strategy, to identify tuberculosis cases among people who use drugs and their household contacts in Kampala, Uganda. Aim 1 screens 2,000 people who use drugs and their household contacts, estimates the number needed to screen to identify one TB case, and compares the effectiveness, reach, and network characteristics of this approach with a clinic-based index case household contact approach. Whole genome sequencing characterizes transmission dynamics. Aim 2 compares individual and combined diagnostic strategies, including chest radiography with computer-aided detection, tongue swab nucleic acid amplification testing, and sputum testing by nucleic acid amplification and mycobacterial culture, and identifies the minimal combination of tests.

Trustees of Boston University (Boston University Medical Campus), under a sub-award dated September 18, 2026, provides implementation science guidance and participates in study team meetings and manuscript preparation. Its Biostatistics and Epidemiology Data Analytics Center oversees statistical analyses for Aim 3 and works on analysis of sequencing data for Aim 2. Walimu, a Ugandan health research institution, under a sub-award dated August 25, 2026, serves as the sub-recipient responsible for all in-country implementation, including participant recruitment, screening, enrollment, informed consent, study interventions, ethical and regulatory approvals, and data collection under Good Clinical Practice.

The period of performance runs from the June 19, 2026 award date through May 31, 2031. The recipient's place of performance is Roxbury, Massachusetts 02118, and study activities are conducted in Kampala, Uganda.

Description

Abstract
Tuberculosis (TB) remains the leading infectious cause of death worldwide. Interruption of transmission is the most effective strategy to reduce incident infections, yet current approaches often fail to reach individuals for timely testing and treatment. This study addresses that GAP by leveraging social networks to identify individuals at highest risk of transmitting TB, specifically, people who use drugs (PWUD). We will evaluate respondent-driven sampling (RDS), a PEER7 based community recruitment strategy, to identify TB cases among PWUD and the household contacts (HHCS) of those with TB disease (RDS-TB) in kampala, uganda. Conducting this work in a high-prevalence setting such as kampala where our team has established expertise allows US to overcome recruitment challenges common in settings in the united states while generating findings that are directly translatable. This is particularly relevant given that higher TB prevalence and larger outbreaks in the united states have been associated with the use of methamphetamine, heroin, and crack/cocaine, drugs that we will study. In aim 1, we will compare the effectiveness and reach of RDS-TB with a traditional clinic-based index case HHC approach for TB case finding. We will screen 2,000 PWUD and their HHCS, estimate the number needed to screen to identify one case of TB disease, and compare the demographic and network characteristics of RDS-TB recruits with clinic-based HHCS. Whole genome sequencing will be used to characterize transmission dynamics. In aim 2, we will compare the yield of individual and combined TB diagnostic strategies for community-based active case finding. Participants will undergo chest radiography with computer-aided detection, tongue swab testing for TB nucleic acid amplification tests (NAAT), and sputum testing for NAAT and mycobacterial culture. We will identify the minimal combination of tests needed to meet world health organization target product profile thresholds for screening. In aim 3, we will define the conditions under which RDS-based screening can effectively interrupt TB transmission. We will develop an agent-based model informed by social network data from individuals with and without TB, incorporating drug use patterns and demographic characteristics. This project will generate a practical, scalable roadmap for social network-based TB active case finding in HIGH28 risk communities. The approach will be readily adaptable to settings in the united states and will inform strategies to interrupt transmission and advance progress toward TB elimination, in alignment with the NIH strategic plan for TB research.

Transactions

Action Obligated Date
Amendment $296,010
Original award $487,764

Subawards

Subrecipient Amount Awarded
The Johns Hopkins University "Dr. Emily Kendall will serve as Subcontract Principal Investigator and provide scientific and operational support to facilitate the adaptation and… $46,152
Trustees Of Boston University "Dr. Brooks will provide guidance and support on the implementation science aspects of the grant. Dr. Horsburgh will participate in weekly team update… $61,915
Walimu This sub-award supports implementation of the TACTIC study in Kampala, Uganda, aligned with the mission of the National Institutes of Health to improve… $296,010

Quick answers

Who received award R01AI191221?

R01AI191221 was awarded to Boston Medical Center Corporation by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 19, 2026.

How much is award R01AI191221 worth?

$783,774 has been obligated on R01AI191221.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award